[
  {
    "title": "STAT+: Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval",
    "link": "https://www.statnews.com/2026/02/23/gossamer-drug-fails-lung-disease-study-will-still-seek-fda-approval/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T13:00:00.000Z",
    "summary": "Gossamer Bio's drug for pulmonary arterial hypertension failed to achieve the primary endpoint of a Phase 3 clinical trial."
  },
  {
    "title": "STAT+: Gilead to buy Arcellx in nearly $8B deal",
    "link": "https://www.statnews.com/2026/02/23/gilead-arcellx-acquisition-car-t-multiple-myeloma/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T11:03:50.000Z",
    "summary": "Gilead Sciences is buying Arcellx in a deal worth $7.8 billion, picking up its partner on a CAR-T therapy for multiple myeloma."
  },
  {
    "title": "STAT+: Novo Nordisk’s next-gen obesity drug stumbles in comparison study",
    "link": "https://www.statnews.com/2026/02/23/novo-nordisk-cagrisema-fail-comparison-trial-zepbound-eli-lilly-obesity/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T10:24:06.000Z",
    "summary": "Novo Nordisk's next-generation obesity drug CagriSema underperformed versus Eli Lilly's Zepbound in a head-to-head study."
  },
  {
    "title": "Women’s heart attack risk rises even if arteries aren’t as clogged as men’s",
    "link": "https://www.statnews.com/2026/02/23/heart-disease-in-women-plaque-scan-risk/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T10:00:00.000Z",
    "summary": "The smaller arteries of women means a little plaque can be more dangerous than it is for men."
  },
  {
    "title": "All about cell therapy process characterization",
    "link": "https://www.biopharmadive.com/spons/all-about-cell-therapy-process-characterization/812719/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-23T10:00:00.000Z",
    "summary": "Why process characterization is the key to consistent, safe, and scalable cell therapies."
  },
  {
    "title": "Small and mighty: single-domain antibodies pack a biological punch",
    "link": "https://www.biopharmadive.com/spons/small-and-mighty-single-domain-antibodies-pack-a-biological-punch/811314/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-23T10:00:00.000Z",
    "summary": "VHH antibodies, they’re not just small, they're modular engineering platforms, capable of powerful biological activity. But with great power comes great challenges!"
  },
  {
    "title": "STAT+: A provocative proposal asks the FDA to let some AI devices on the market without review",
    "link": "https://www.statnews.com/2026/02/23/harrisonai-fda-petition-exempt-ai-devices-premarket-review/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T09:30:00.000Z",
    "summary": "A provocative new proposal has offered the FDA a way to let a broad swath of potentially risky AI devices flood the market."
  },
  {
    "title": "STAT+: Health care reform might be a focus in midterms. For Congress, pursuing it will be an uphill climb",
    "link": "https://www.statnews.com/2026/02/23/health-care-reform-midterms-trump/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T09:30:00.000Z",
    "summary": "Lawmakers will likely have a lot to say about health care this year. Paradoxically, they probably won't accomplish much on the subject."
  },
  {
    "title": "Opinion: No one in health care should be called a ‘provider’",
    "link": "https://www.statnews.com/2026/02/23/provider-ethical-objections-physician-acp/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T09:30:00.000Z",
    "summary": "The word “provider” in health care turns the relationship between patient and physician into a commercial transaction, argues the American College of Physicians."
  },
  {
    "title": "STAT+: Lobbying firms with close ties to Trump draw pharma industry clients",
    "link": "https://www.statnews.com/2026/02/23/fda-lobbying-trump-connected-firms-cash-in/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T09:30:00.000Z",
    "summary": "Business is booming for Trump-connected lobbying firms as pharma giants see new opportunity to influence the FDA."
  },
  {
    "title": "STAT+: Pharma lobbyists focus on a surprising new target: the FDA",
    "link": "https://www.statnews.com/2026/02/23/fda-lobbying-efforts-grow-under-trump-administration/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T09:30:00.000Z",
    "summary": "Lobbyists told STAT they believe the odds of approval go up if a decision can be spun as a win for the Trump administration."
  },
  {
    "title": "STAT+: Nature Medicine to investigate  study that found cancer treatment is better in morning",
    "link": "https://www.statnews.com/2026/02/20/cancer-immunotherapy-morning-infusions-doubts-about-study/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-21T01:13:11.000Z",
    "summary": "Nature Medicine starts an investigation into inconsistencies in a study that found it was better to have immunotherapy in the morning."
  },
  {
    "title": "STAT+: DOJ, Ohio attorney general accuse OhioHealth of driving up prices, crowding out competition",
    "link": "https://www.statnews.com/2026/02/20/doj-ohio-antitrust-lawsuit-ohiohealth-acontracts/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-20T21:17:59.000Z",
    "summary": "Regulators say Ohio hospital system made it difficult for health insurers to offer cheaper plans."
  },
  {
    "title": "Grail’s multi-cancer early detection test misses study goal",
    "link": "https://www.biopharmadive.com/news/grails-multi-cancer-early-detection-test-misses-study-goal/812744/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-20T19:16:43.000Z",
    "summary": "Shares in the company lost about half their value in Friday trading after use of the test wasn’t associated with a statistically significant reduction in late-stage cancer diagnoses."
  },
  {
    "title": "Supreme Court invalidates Trump tariffs based on emergency powers",
    "link": "https://www.biopharmadive.com/news/supreme-court-invalidates-trump-tariffs-based-on-emergency-powers/812723/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-20T18:57:00.000Z",
    "summary": "In a 6-3 decision, the court rejected President Trump's claim that a 1977 law gave him the authority to impose broad tariffs globally."
  },
  {
    "title": "Roche gets FDA decision date on closely watched breast cancer drug",
    "link": "https://www.biopharmadive.com/news/roche-giredestrant-serd-fda-approval-decision-breast-cancer/812695/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-20T17:16:22.000Z",
    "summary": "The agency could by late December approve a therapy that Roche sees as potentially becoming a new treatment standard for certain breast tumors."
  },
  {
    "title": "Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi",
    "link": "https://www.biopharmadive.com/news/madrigal-earnings-daiichi-tsai-acimmune-alzheimers-novartis-unnatural/812565/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-20T15:23:00.000Z",
    "summary": "Madrigal shares fell 11% despite again topping consensus sales numbers. Elsewhere, Daiichi Sankyo named a new research chief and J&J halted recruitment in an Alzheimer’s trial."
  },
  {
    "title": "STAT+: Up and down the ladder: The latest comings and goings",
    "link": "https://www.statnews.com/pharmalot/2026/02/20/pharma-biotech-jobs-roche-sanofi-daiichi/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-20T14:52:46.000Z",
    "summary": "From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry."
  },
  {
    "title": "STAT+: Element Biosciences launches table-top sequencer capable of $100 genome",
    "link": "https://www.statnews.com/2026/02/20/biotech-news-element-biosciences-100-dollar-genome/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-20T14:32:31.000Z",
    "summary": "And other biotech news brought to you by The Readout newsletter"
  },
  {
    "title": "STAT+: Pharmalittle: We’re reading about an FDA official’s speech, a Grail cancer blood test, and much more",
    "link": "https://www.statnews.com/pharmalot/2026/02/20/fda-cancer-antibiotics-kickbacks-otc-patents-covid/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-20T14:26:16.000Z",
    "summary": "The FDA's top drug regulator indicated in her first address to staff that she will scrutinize antidepressants and shots used to protect babies from RSV"
  },
  {
    "title": "ACIP meeting postponed, for reasons that are unclear",
    "link": "https://www.statnews.com/2026/02/20/health-news-acip-meeting-postponed-covid-19/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-20T12:55:15.000Z",
    "summary": "And other health news from today's Morning Rounds newsletter"
  },
  {
    "title": "AI is slashing jobs across industries. Will pharma be next?",
    "link": "https://www.biopharmadive.com/news/ai-biotech-pharma-jobs-layoffs-amazon-nvidia-pharma/812635/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-20T11:28:00.000Z",
    "summary": "Despite a wave of AI-fueled layoffs, the pharma and biotech industries could be spared from massive cutbacks for now."
  },
  {
    "title": "With federal research funding uncertain, states debate new science initiatives",
    "link": "https://www.statnews.com/2026/02/20/states-fill-nih-funding-gap-trump-cuts/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-20T09:30:00.000Z",
    "summary": "A handful of states are considering initiatives to increase funding for scientific research as uncertainty around federal dollars has grown."
  },
  {
    "title": "Biohackers and wellness influencers are pushing nicotine as part of their ‘stacks’",
    "link": "https://www.statnews.com/2026/02/20/nicotine-wellness-startups-productivity-boost-legal-gray-area/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-20T09:30:00.000Z",
    "summary": "As smoking rates fall in the U.S., startups and influencers are pushing the purported cognitive and health benefits of indulging in nicotine."
  },
  {
    "title": "Would you trust AI to renew your drug prescriptions?",
    "link": "https://www.statnews.com/2026/02/20/doctronic-ai-physician-chatbot-explored-alex-hogan-status-report/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-20T09:30:00.000Z",
    "summary": "Would you trust AI to renew your drug prescriptions? Alex Hogan explores the question on this week's episode of STATus Report."
  },
  {
    "title": "Opinion: On ‘The Pitt,’ art catches up with the medical debt crisis",
    "link": "https://www.statnews.com/2026/02/20/tv-show-the-pitt-highlights-medical-debt-crisis/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-20T09:30:00.000Z",
    "summary": "Joe Sachs, a physician and executive producer on “The Pitt,” and the CEO of Undue Medical Debt weigh in on the show’s foray into a health care crisis."
  },
  {
    "title": "Opinion: STAT+: Sometimes, it would be unethical not to use AI in medicine",
    "link": "https://www.statnews.com/2026/02/20/ai-medical-ethics-doctors-unethical-not-use-ai/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-20T09:30:00.000Z",
    "summary": "“We do not let pilots fly without instrument support simply because they technically could. Why should medicine be different?”"
  },
  {
    "title": "Clearing cholesterol combats secondary lymphoedema",
    "link": "https://www.nature.com/articles/d41573-026-00032-6",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-20T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "The pancreatic cancer drug market",
    "link": "https://www.nature.com/articles/d41573-026-00027-3",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-20T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "Altesa, run by former Trump official, raises $75M for well-traveled lung drug",
    "link": "https://www.biopharmadive.com/news/Altesa-biotech-startup-financing-giroir-vapendavir-copd-lung/812566/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-19T17:06:00.000Z",
    "summary": "Led by Brett Giroir and GSK’s ex-chief medical officer, Altesa is advancing a medicine that’s changed hands multiple times and once failed a study in asthma."
  },
  {
    "title": "FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals",
    "link": "https://www.biopharmadive.com/news/fda-makary-prasad0one-pivotal-trial-nejm/812557/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-19T16:20:00.000Z",
    "summary": "In a NEJM article, Commissioner Martin Makary and top deputy Vinay Prasad argued that the new policy should lower development costs and speed development without compromising agency standards."
  },
  {
    "title": "Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6",
    "link": "https://www.biopharmadive.com/news/lilly-deal-csl-100m-license-monoclonal-antibody-targeting-il-6/812455/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-18T16:15:18.000Z",
    "summary": "The Australian company will retain rights for an end-stage kidney disease indication currently being tested in a Phase 3 trial while Lilly explores other uses."
  },
  {
    "title": "PIP4K2C: an emerging fulcrum for multiple diseases",
    "link": "https://www.nature.com/articles/d41573-026-00030-8",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-18T00:00:00.000Z",
    "summary": ""
  }
]
